Raptor Pharmaceutical Inc. (RPTP) Release: Data Published In Journal Of Pediatrics Demonstrated That PROCYSBI® Improved Quality Of Life And Preserved Kidney Function In Cystinosis Patients
6/24/2014 8:42:10 AM
NOVATO, Calif., June 24, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that data from its open label extension study of delayed-release cysteamine bitartrate (PROCYSBI®) has been published in the Journal of Pediatrics [DOI: 10.1016/j.jpeds.2014.05.013]. The study demonstrated that patients with nephropathic cystinosis who took PROCYSBI for two years were able to sustain optimal cystine control in their white blood cells and preserve kidney function over the long term, and had significant improvements in social, school and total functioning based on validated quality of life measurement scales.
Help employers find you! Check out all the jobs and post your resume.
comments powered by